Huntington's disease (HD) is a fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Previously, we showed strong huntingtin reduction and prevention of neuronal dysfunction in HD rodents using an engineered microRNA targeting human huntingtin, delivered via adeno-associated virus (AAV) serotype 5 vector with a transgene encoding an engineered miRNA against HTT mRNA (AAV5-miHTT). One of the challenges of rodents as a model of neurodegenerative diseases is their relatively small brain, making successful translation to the HD patient difficult. This is particularly relevant for gene therapy approaches, where distribution achieved upon local administration into the parenchyma is likely dependent on brain size and structure. Here, we aimed to demonstrate the translation of huntingtin-lowering gene therapy to a large-animal brain. We investigated the feasibility, efficacy, and tolerability of one-time intracranial administration of AAV5-miHTT in the transgenic HD (tgHD) minipig model. We detected widespread dose-dependent distribution of AAV5-miHTT throughout the tgHD minipig brain that correlated with the engineered microRNA expression. Both human mutant huntingtin mRNA and protein were significantly reduced in all brain regions transduced by AAV5-miHTT. The combination of widespread vector distribution and extensive huntingtin lowering observed with AAV5-miHTT supports the translation of a huntingtin-lowering gene therapy for HD from preclinical studies into the clinic.

Department of Research and Development uniQure biopharma B 5 Amsterdam the Netherlands

Institute of Animal Physiology and Genetics Libechov Czech Republic

Zobrazit více v PubMed

Waldvogel H.J., Kim E.H., Tippett L.J., Vonsattel J.P., Faull R.L. The neuropathology of Huntington’s disease. Curr. Top. Behav. Neurosci. 2015;22:33–80. PubMed

Rüb U., Seidel K., Heinsen H., Vonsattel J.P., den Dunnen W.F., Korf H.W. Huntington’s disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain Pathol. 2016;26:726–740. PubMed PMC

Ross C.A., Pantelyat A., Kogan J., Brandt J. Determinants of functional disability in Huntington’s disease: role of cognitive and motor dysfunction. Mov. Disord. 2014;29:1351–1358. PubMed PMC

Ross C.A., Tabrizi S.J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83–98. PubMed

Boudreau R.L., McBride J.L., Martins I., Shen S., Xing Y., Carter B.J., Davidson B.L. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol. Ther. 2009;17:1053–1063. PubMed PMC

Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., Bonvento G., Brouillet E., Luthi-Carter R., Hantraye P., Déglon N. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009;65:276–285. PubMed

Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., Artates J.W., Weiss A., Cheng S.H., Shihabuddin L.S. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031–1044. PubMed PMC

Evers M.M., Pepers B.A., van Deutekom J.C., Mulders S.A., den Dunnen J.T., Aartsma-Rus A., van Ommen G.J., van Roon-Mom W.M. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE. 2011;6:e24308. PubMed PMC

Hu J., Matsui M., Gagnon K.T., Schwartz J.C., Gabillet S., Arar K., Wu J., Bezprozvanny I., Corey D.R. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 2009;27:478–484. PubMed PMC

McBride J.L., Pitzer M.R., Boudreau R.L., Dufour B., Hobbs T., Ojeda S.R., Davidson B.L. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol. Ther. 2011;19:2152–2162. PubMed PMC

Carroll J.B., Warby S.C., Southwell A.L., Doty C.N., Greenlee S., Skotte N., Hung G., Bennett C.F., Freier S.M., Hayden M.R. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol. Ther. 2011;19:2178–2185. PubMed PMC

Stanek L.M., Sardi S.P., Mastis B., Richards A.R., Treleaven C.M., Taksir T., Misra K., Cheng S.H., Shihabuddin L.S. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum. Gene Ther. 2014;25:461–474. PubMed PMC

Cambon K., Zimmer V., Martineau S., Gaillard M.C., Jarrige M., Bugi A., Miniarikova J., Rey M., Hassig R., Dufour N. Preclinical evaluation of a lentiviral vector for Huntingtin silencing. Mol. Ther. Methods Clin. Dev. 2017;5:259–276. PubMed PMC

Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc. Natl. Acad. Sci. USA. 2005;102:5820–5825. PubMed PMC

Datson N.A., González-Barriga A., Kourkouta E., Weij R., van de Giessen J., Mulders S., Kontkanen O., Heikkinen T., Lehtimäki K., van Deutekom J.C. The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS ONE. 2017;12:e0171127. PubMed PMC

Ionis Pharmaceuticals, Inc. (2015). Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-HTTRx in patients with early manifest Huntington’s disease. https://clinicaltrials.gov/ct2/show/NCT02519036.

Grondin R., Ge P., Chen Q., Sutherland J.E., Zhang Z., Gash D.M., Stiles D.K., Stewart G.R., Sah D.W., Kaemmerer W.F. Onset time and durability of Huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA. Mol. Ther. Nucleic Acids. 2015;4:e245. PubMed PMC

Machida Y., Okada T., Kurosawa M., Oyama F., Ozawa K., Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 2006;343:190–197. PubMed

Monteys A.M., Wilson M.J., Boudreau R.L., Spengler R.M., Davidson B.L. Artificial miRNAs targeting mutant Huntingtin show preferential silencing in vitro and in vivo. Mol. Ther. Nucleic Acids. 2015;4:e234. PubMed

Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol. Ther. 2005;12:618–633. PubMed PMC

Miniarikova J., Zimmer V., Martier R., Brouwers C.C., Pythoud C., Richetin K., Rey M., Lubelski J., Evers M.M., van Deventer S.J. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 2017;24:630–639. PubMed PMC

Boudreau R.L., Spengler R.M., Davidson B.L. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington’s disease. Mol. Ther. 2011;19:2169–2177. PubMed PMC

McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA. 2008;105:5868–5873. PubMed PMC

Monteys A.M., Spengler R.M., Dufour B.D., Wilson M.S., Oakley C.K., Sowada M.J., McBride J.L., Davidson B.L. Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res. 2014;42:13315–13327. PubMed PMC

Southwell A.L., Skotte N.H., Villanueva E.B., Østergaard M.E., Gu X., Kordasiewicz H.B., Kay C., Cheung D., Xie Y., Waltl S. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum. Mol. Genet. 2017;26:1115–1132. PubMed

Miniarikova J., Zanella I., Huseinovic A., van der Zon T., Hanemaaijer E., Martier R., Koornneef A., Southwell A.L., Hayden M.R., van Deventer S.J. Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington’s disease. Mol. Ther. Nucleic Acids. 2016;5:e297. PubMed PMC

Venuto C.S., McGarry A., Ma Q., Kieburtz K. Pharmacologic approaches to the treatment of Huntington’s disease. Mov. Disord. 2012;27:31–41. PubMed

Travessa A.M., Rodrigues F.B., Mestre T.A., Ferreira J.J. Fifteen years of clinical trials in Huntington’s disease: a very low clinical drug development success rate. J. Huntingtons Dis. 2017;6:157–163. PubMed

Morton A.J., Howland D.S. Large genetic animal models of Huntington’s disease. J. Huntingtons Dis. 2013;2:3–19. PubMed

Baxa M., Hruska-Plochan M., Juhas S., Vodicka P., Pavlok A., Juhasova J., Miyanohara A., Nejime T., Klima J., Macakova M. A transgenic minipig model of Huntington’s disease. J. Huntingtons Dis. 2013;2:47–68. PubMed

Jacobsen J.C., Bawden C.S., Rudiger S.R., McLaughlan C.J., Reid S.J., Waldvogel H.J., MacDonald M.E., Gusella J.F., Walker S.K., Kelly J.M. An ovine transgenic Huntington’s disease model. Hum. Mol. Genet. 2010;19:1873–1882. PubMed PMC

Gasmi M., Herzog C.D., Brandon E.P., Cunningham J.J., Ramirez G.A., Ketchum E.T., Bartus R.T. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson’s disease. Mol. Ther. 2007;15:62–68. PubMed

Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., Zabner J., Ghodsi A., Chiorini J.A. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA. 2000;97:3428–3432. PubMed PMC

Wild E.J., Boggio R., Langbehn D., Robertson N., Haider S., Miller J.R., Zetterberg H., Leavitt B.R., Kuhn R., Tabrizi S.J. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J. Clin. Invest. 2015;125:1979–1986. PubMed PMC

Valekova I., Jarkovska K., Kotrcova E., Bucci J., Ellederova Z., Juhas S., Motlik J., Gadher S.J., Kovarova H. Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington’s disease model. J. Neuroimmunol. 2016;293:71–81. PubMed

Samaranch L., Sebastian W.S., Kells A.P., Salegio E.A., Heller G., Bringas J.R., Pivirotto P., DeArmond S., Forsayeth J., Bankiewicz K.S. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol. Ther. 2014;22:329–337. PubMed PMC

Schramke S., Schubert R., Frank F., Wirsig M., Fels M., Kemper N., Schuldenzucker V., Reilmann R. The Libechov minipig as a large animal model for preclinical research in Huntington’s disease – thoughts and perspectives. Cesk. Neurol. Neurochir. 2015;78/111(Suppl 2):55–60.

Schuldenzucker V., Schubert R., Muratori L.M., Freisfeld F., Rieke L., Matheis T., Schramke S., Motlik J., Kemper N., Radespiel U., Reilmann R. Behavioral testing of minipigs transgenic for the Huntington gene—a three-year observational study. PLoS ONE. 2017;12:e0185970. PubMed PMC

Howland D.S., Munoz-Sanjuan I. Mind the gap: models in multiple species needed for therapeutic development in Huntington’s disease. Mov. Disord. 2014;29:1397–1403. PubMed

Samaranch L., Blits B., San Sebastian W., Hadaczek P., Bringas J., Sudhakar V., Macayan M., Pivirotto P.J., Petry H., Bankiewicz K.S. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther. 2017;24:253–261. PubMed PMC

Shaffer J.J., Ghayoor A., Long J.D., Kim R.E., Lourens S., O’Donnell L.J., Westin C.F., Rathi Y., Magnotta V., Paulsen J.S., Johnson H.J. Longitudinal diffusion changes in prodromal and early HD: evidence of white-matter tract deterioration. Hum. Brain Mapp. 2017;38:1460–1477. PubMed PMC

Grondin R., Kaytor M.D., Ai Y., Nelson P.T., Thakker D.R., Heisel J., Weatherspoon M.R., Blum J.L., Burright E.N., Zhang Z., Kaemmerer W.F. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135:1197–1209. PubMed PMC

Trajkovic K., Jeong H., Krainc D. Mutant Huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway. J. Neurosci. 2017;37:9000–9012. PubMed PMC

Southwell A.L., Smith S.E., Davis T.R., Caron N.S., Villanueva E.B., Xie Y., Collins J.A., Ye M.L., Sturrock A., Leavitt B.R. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci. Rep. 2015;5:12166. PubMed PMC

Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science. 1995;269:407–410. PubMed

Lopes F., Barbosa M., Ameur A., Soares G., de Sá J., Dias A.I., Oliveira G., Cabral P., Temudo T., Calado E. Identification of novel genetic causes of Rett syndrome-like phenotypes. J. Med. Genet. 2016;53:190–199. PubMed

Nasir J., Floresco S.B., O’Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., Hayden M.R. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:811–823. PubMed

Rodan L.H., Cohen J., Fatemi A., Gillis T., Lucente D., Gusella J., Picker J.D. A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene. Eur. J. Hum. Genet. 2016;24:1826–1827. PubMed PMC

Stiles D.K., Zhang Z., Ge P., Nelson B., Grondin R., Ai Y., Hardy P., Nelson P.T., Guzaev A.P., Butt M.T. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp. Neurol. 2012;233:463–471. PubMed

Wang G., Liu X., Gaertig M.A., Li S., Li X.J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl. Acad. Sci. USA. 2016;113:3359–3364. PubMed PMC

Dietrich P., Johnson I.M., Alli S., Dragatsis I. Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 2017;13:e1006846. PubMed PMC

Björkqvist M., Wild E.J., Thiele J., Silvestroni A., Andre R., Lahiri N., Raibon E., Lee R.V., Benn C.L., Soulet D. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J. Exp. Med. 2008;205:1869–1877. PubMed PMC

Crotti A., Benner C., Kerman B.E., Gosselin D., Lagier-Tourenne C., Zuccato C., Cattaneo E., Gage F.H., Cleveland D.W., Glass C.K. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 2014;17:513–521. PubMed PMC

Cicchetti F., Barker R.A. The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Front. Pharmacol. 2014;5:139. PubMed PMC

Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 2005;11:703–704. PubMed

Keene C.D., Chang R.C., Leverenz J.B., Kopyov O., Perlman S., Hevner R.F., Born D.E., Bird T.D., Montine T.J. A patient with Huntington’s disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 2009;117:329–338. PubMed PMC

Tuszynski M.H., Thal L., Pay M., Salmon D.P., U H.S., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005;11:551–555. PubMed

Wojtecki L., Groiss S.J., Hartmann C.J., Elben S., Omlor S., Schnitzler A., Vesper J. Deep brain stimulation in Huntington’s disease—preliminary evidence on pathophysiology, efficacy and safety. Brain Sci. 2016;6:E38. PubMed PMC

Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006;59:459–466. PubMed

Mittermeyer G., Christine C.W., Rosenbluth K.H., Baker S.L., Starr P., Larson P., Kaplan P.L., Forsayeth J., Aminoff M.J., Bankiewicz K.S. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson’s disease. Hum. Gene Ther. 2012;23:377–381. PubMed PMC

Deverman B.E., Pravdo P.L., Simpson B.P., Kumar S.R., Chan K.Y., Banerjee A., Wu W.L., Yang B., Huber N., Pasca S.P., Gradinaru V. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 2016;34:204–209. PubMed PMC

Chan K.Y., Jang M.J., Yoo B.B., Greenbaum A., Ravi N., Wu W.L., Sánchez-Guardado L., Lois C., Mazmanian S.K., Deverman B.E., Gradinaru V. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 2017;20:1172–1179. PubMed PMC

Carroll J.B., Bates G.P., Steffan J., Saft C., Tabrizi S.J. Treating the whole body in Huntington’s disease. Lancet Neurol. 2015;14:1135–1142. PubMed

Unzu C., Hervás-Stubbs S., Sampedro A., Mauleón I., Mancheño U., Alfaro C., de Salamanca R.E., Benito A., Beattie S.G., Petry H. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J. Transl. Med. 2012;10:122. PubMed PMC

Urabe M., Ding C., Kotin R.M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002;13:1935–1943. PubMed

Majowicz A., Salas D., Zabaleta N., Rodríguez-Garcia E., González-Aseguinolaza G., Petry H., Ferreira V. Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1. Mol. Ther. 2017;25:1831–1842. PubMed PMC

Glud A.N., Hedegaard C., Nielsen M.S., Søorensen J.C., Bendixen C., Jensen P.H., Mogensen P.H., Larsen K., Bjarkam C.R. Direct MRI-guided stereotaxic viral mediated gene transfer of alpha-synuclein in the Göttingen minipig CNS. Acta Neurobiol. Exp. (Warsz.) 2011;71:508–518. PubMed

Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45. PubMed PMC

Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33:e179. PubMed PMC

R_Core_Team. (2017). R: a language and environment for statistical computing. https://www.R-project.org.

Sanz, H., Aponte, J., Harezlak, J., Dong, Y., Murawska, M., Valim, C., Ayestaran, A., Aguilar, R., and Moncunill, G. (2015). drLumi: multiplex immunoassays data analysis. R package version 0.1.2 (The R Foundation). https://cran.r-project.org/web/packages/drLumi/index.html.

Félix B., Léger M.E., Albe-Fessard D., Marcilloux J.C., Rampin O., Laplace J.P. Stereotaxic atlas of the pig brain. Brain Res. Bull. 1999;49:1–137. PubMed

Mitochondrial Dysfunction in a High Intraocular Pressure-Induced Retinal Ischemia Minipig Model

Huntingtin Co-Isolates with Small Extracellular Vesicles from Blood Plasma of TgHD and KI-HD Pig Models of Huntington's Disease and Human Blood Plasma

Krankheitsmodifizierende Therapieansätze bei der Huntington-Krankheit : Blicke zurück und Blicke voraus

Emerging Roles of Exosomes in Huntington's Disease

Large Animal Models of Huntington's Disease: What We Have Learned and Where We Need to Go Next

Genselektive Therapieansätze bei der Huntington-Krankheit

Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease

Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington's disease

Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration